Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Inclusion Criteria: * Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria: * Stage I-IV disease * No morphologically unclassifiable disease * Meets 1 of the following criteria: * Mixed cellularity * Lymphocytic depletion (LD) * LD, diffuse fibrosis * LD, reticular * Lymphocyte predominance (LP) * LP, diffuse * LP, nodular * Nodular sclerosis (NS) * NS, cellular phase * NS, lymphocytic predominance * NS, mixed cellularity * NS, LD * Not otherwise specified * Primary refractory disease OR disease in first relapse, except for the following: * Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy * Patients on the observation-only arm of protocol COG-AHOD0431 * Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney) * Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met: * Platelet count ≥ 20,000/mm³ (platelet transfusion allowed) * Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed) * Karnofsky performance status (PS) 60-100% (for patients \> 16 years of age) OR Lanksy PS 60-100% (for patients =\< 16 years of age) * Life expectancy \>= 2 months * Absolute neutrophil count \>= 1,000/mm\^3 * Platelet count \>= 75,000/mm\^3 (transfusion independent) (for patients with no bone marrow involvement) * Creatinine =\< 1.5 times upper limit of normal (ULN) * Creatinine clearance or radioisotope glomerular filtration rate \>= 70 mL/min/1.73 m\^2 * AST and ALT =\< 2.5 times ULN * Bilirubin =\< 1.5 times ULN * Shortening fraction \>= 27% by echocardiogram OR LVEF \>= 50% by gated radionuclide study * Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled * No CNS toxicity \> grade 2 * No serious intercurrent illnesses * No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs * No peripheral neuropathy \> grade 1 * No known hypersensitivity to bortezomib, boron, or mannitol * No other concurrent chemotherapy or immunomodulating agents (including steroids) * Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions * No dexamethasone or aprepitant as an antiemetic * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Recovered from prior therapy * No prior bortezomib or other proteasome inhibitors * At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas) * More than 14 days since prior investigational drugs * No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants * Benzodiazepine or gabapentin allowed